Ustekinumab

被引：20

作者：

Reich, Kristian ^{[1
]}

Yasothan, Uma ^{[2
]}

Kirkpatrick, Peter

机构：

[1] Dermatologikum Hamburg, D-20354 Hamburg, Germany

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2009年 / 8卷 / 05期

关键词：

INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; PLAQUE-TYPE PSORIASIS; QUALITY-OF-LIFE; DOUBLE-BLIND; SKIN; EFFICACY; SAFETY; TRIAL; METAANALYSIS; EXPRESSION;

D O I：

10.1038/nrd2878

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

In January 2009, ustekinumab (Stelara; Janssen Cilag) was granted marketing authorization by the European Commission for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other therapies including cyclosporine, methotrexate and phototherapy.

引用

收藏

页码：355 / 356

页数：2

相关论文

共 20 条

[1]

Disease severity, quality of life and health care in plaque-type psoriasis:: A multicenter cross-sectional study in Germany [J].

Augustin, M. ;

Krueger, K. ;

Radtke, M. A. ;

Schwippl, I. ;

Reich, K. .

DERMATOLOGY, 2008, 216 (04) :366-372

[2]

European patient perspectives on the impact of psoriasis:: the EUROPSO patient membership survey [J].

Dubertret, L. ;

Mrowietz, U. ;

Ranki, A. ;

van de Kerkhof, P. C. M. ;

Chimenti, S. ;

Lotti, T. ;

Schaefer, G. .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) :729-736

[3]

*EMEA, 2008, EUR PUBL ASS REP STE

[4]

Psoriasis: Emerging therapeutic strategies [J].

Gottlieb, AB .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (01) :19-34

[5]

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial [J].

Gottlieb, Alice ;

Menter, Alan ;

Mendelsohn, Alan ;

Shen, Yaung-Kaung ;

Li, Shu ;

Guzzo, Cynthia ;

Fretzin, Scott ;

Kunynetz, Rod ;

Kavanaugh, Arthur .

LANCET, 2009, 373 (9664) :633-640

[6]

Hong K, 1999, J IMMUNOL, V162, P7480

[7]

A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis [J].

Kauffman, CL ;

Aria, N ;

Toichi, E ;

McCormick, TS ;

Cooper, KD ;

Gottlieb, AB ;

Everitt, DE ;

Frederick, B ;

Zhu, YW ;

Graham, MA ;

Pendley, CE ;

Mascelli, MA .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (06) :1037-1044

[8]

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis [J].

Krueger, Gerald G. ;

Langley, Richard G. ;

Leonardi, Craig ;

Yeilding, Newman ;

Guzzo, Cynthia ;

Wang, Yuhua ;

Dooley, Lisa T. ;

Lebwohl, Mark .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (06) :580-592

[9]

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris [J].

Lee, E ;

Trepicchio, WL ;

Oestreicher, JL ;

Pittman, D ;

Wang, F ;

Chamian, F ;

Dhodapkar, M ;

Krueger, JG .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (01) :125-130

[10]

Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4